Abeona (ABEO) director granted 37,313 restricted shares vesting in 2027

Rhea-AI Filing Summary

Abeona Therapeutics director Faith L. Charles received an equity grant of 37,313 shares of common stock as restricted stock on January 26, 2026. The award was reported at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.

Following this grant, Charles beneficially owns 176,407 shares of Abeona common stock in direct form. All of the restricted stock from this award is scheduled to vest on January 26, 2027, aligning her compensation with the company’s future performance over the vesting period.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Charles Faith L.

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		37,313(1)	A	$0.00	176,407	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All of the restricted stock will vest on January 26, 2027.

	/s/ Faith L. Charles	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Abeona Therapeutics (ABEO) disclose in this Form 4 filing?

Abeona Therapeutics disclosed that director Faith L. Charles received 37,313 shares of restricted common stock on January 26, 2026. The shares were granted at $0.00 per share as equity compensation and increase her direct beneficial ownership in the company.

How many Abeona (ABEO) shares does director Faith L. Charles now own?

After the reported transaction, director Faith L. Charles beneficially owns 176,407 shares of Abeona common stock. This total reflects the addition of 37,313 restricted shares granted on January 26, 2026, as part of her director compensation package.

When do the newly granted Abeona (ABEO) restricted shares vest?

All 37,313 shares of restricted Abeona common stock granted to director Faith L. Charles will vest on January 26, 2027. This one-year vesting schedule ties the value of the award to her continued service and the company’s performance over that period.

Was cash paid for the Abeona (ABEO) shares reported in this Form 4?

No cash was paid for these shares. The Form 4 shows 37,313 shares of Abeona common stock granted at a price of $0.00 per share, indicating they were issued as restricted stock compensation rather than purchased in the open market.

Is the Abeona (ABEO) Form 4 transaction a purchase or a grant?

The transaction is a stock grant, not a market purchase. The Form 4 reports 37,313 shares of restricted Abeona common stock acquired with a transaction code "A" at $0.00 per share, consistent with an equity compensation award to director Faith L. Charles.

What role does the reporting person have at Abeona Therapeutics (ABEO)?

The reporting person, Faith L. Charles, serves as a director of Abeona Therapeutics. The Form 4 indicates her relationship as a director and shows that the reported 37,313-share restricted stock grant increases her direct beneficial ownership in the company.